Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07369934

Virtual Reality Based Exercise Training Versus Mulligan Mobilization on Shoulder Posture and Function in Subacromial Impingement Syndrome

The study will compare the effect of virtual reality based exercise training versus Mulligan mobilization in addition to exercise therapy added to both groups on shoulder posture and function in subacromial impingement syndrome.

Recruiting

Interested in participating?

Request Info

Key information

Age range

30 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Faculty of Physical Therapy, Cairo University

Giza, Egypt

Location status: Recruiting

Location contact

Afaf M Tahoon, lecturer

CONTACT

[email protected]

+01015401783

Sara M Meselhy, Demostrator

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients will be referred from the orthopedic surgeon with a diagnosis of stage II SIS with the following criteria:
  • Participants ranged in age from 30-50 years old.
  • Participants are from non-athletes from the general population.
  • Unilateral shoulder pain that is localized either anteriorly or laterally to the acromion. Pain that occurs or worsens when the affected shoulder is in flexion and/or abduction.
  • Four of the following should be present in the included patients: Neer impingement test, Hawkins' test, Pain was replicated in the supraspinatus empty-can test, a painful arc of movement from 70° to 120°, and painful greater tuberosity of the humerus.
  • BMI range 18.5- 29.9 Kg/m².

Exclusion criteria

  • 1) Patients who, during the previous three months, underwent shoulder physical treatment and/or an acute pain flare.
  • Patients who have undergone surgeries for tendon repair. 3) Malignancy, epilepsy, pregnant women, and/or systemic conditions like chronic renal or liver failure.
  • Mini-Mental State Examination test (MMSE) (< 24/30) to exclude cognitive impairment and/or significant vision impairment (if they couldn't read the introduction while wearing the Head Mounted Device (HMD).
  • Corticosteroid injection during the last three months or used steroids chronically.
  • Adhesive capsulitis, glenohumeral joint instability, Numbness or tingling of the upper limb, and/or full-thickness tear of the rotator cuff.

Treatment and study plan

Virtual Reality

Other

Fully immersive virtual reality mounted headset will be used

Mulligan mobilization

Other

posterolateral shoulder Mulligan mobilization with movement (MWM) will be used

Primary outcomes

  1. Pain intensity during shoulder elevation

    Time frame: pain intensity at the start of session 1 to the end of 1 month of treatment

    It will be measured using the Numerical Pain Rating Scale (NPRS)

  2. Shoulder function

    Time frame: shoulder function at the start of session 1 to the end of 1 month of treatment

    The Shoulder Pain and Disability Index (SPADI) will be used to measure the shoulder function.

  3. Shoulder flexion range of motion

    Time frame: shoulder flexion at the start of session 1 to the end of 1 month of treatment

    The Clinometer Application will be used to measure it.

  4. Shoulder abduction range of motion

    Time frame: shoulder abduction at the start of session 1 to the end of 1 month of treatment

    The Clinometer Application will be used to measure it.

  5. shoulder posture

    Time frame: shoulder posture at the start of session 1 to the end of 1 month of treatment

    Sagittal Shoulder Angle will be used to measure the shoulder posture

Secondary outcomes

  1. Patients' enjoyment

    Time frame: It will be evaluated at the end of the last session (after 1 month)

    A 7-point likert scale will be used to the evaluate the level of the patients' enjoyment at the end of the last session.

  2. patients' adherence to treatment sessions

    Time frame: patients' adherence at the start of session 1 to the end of 1 month of treatment

    patients' numbers of attended sessions will be calculated at the end of 1 month of treatment.

Study contacts

Contact information is provided by the study sponsor or research team.

Afaf M Tahoon, lecturer

CONTACT

[email protected]

+01015401783

Sara M Meselhy, Demonstrator

CONTACT

[email protected]

+01222518092

Sponsors and collaborators

Lead sponsor

Cairo University

Other

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jan 27, 2026
Registry last updated
Jan 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.